🇺🇸 FDA

Company profile · Sponsor

Karyopharm

Karyopharm Therapeutics

KPTI · NYSE pharma NEWTON, MA, USA
Pipeline
24
Drugs
1
Patents
8

Quick answer

Karyopharm (KPTI) is a pharma company. headquartered in NEWTON, MA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 8 patents to this profile..

Company facts

Ticker KPTI
Exchange NYSE
Company type pharma
Headquarters NEWTON, MA, USA
SEC CIK 0001503802

Pipeline (24)

Search pipeline →

  1. ONDANSETRON ZYDUS 8 mg, comprimé orodispersible, Jakavi 5 mg tablets, EMEND 125 mg+80 mg hard capsules, Jakavi 15 mg tablets, Jakavi 20 mg tablets, PALONOSETRON, NETUPITANT, Akynzeo 300 mg/0.5 mg hard capsules, Selinexor placebo for 20 mg tablets formulated for oral administration., Jakavi 10 mg tablets, SELINEXOR, ONDANSETRON

    Karyopharm

    Treatment naïve patients with MF

    phase 3 small molecule active

    1 trial

  2. Ondansetron Aurobindo 8 mg Filmtabletten, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Dexametazona Krka 4 mg comprimate, EMEND 125 mg+80 mg hard capsules, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, G

    Karyopharm

    Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

    phase 3 small molecule active

    1 trial

  3. SELINEXOR, Selinexor placebo for 20 mg tablets is formulated for oral administration. selinexor placebo tablets are film coated bi-convex round tablets

    Karyopharm

    endometrial cancer

    phase 3 small molecule active

    1 trial

  4. Selinexor

    Karyopharm

    Multiple Myeloma

    phase 3 small molecule active

    12 trials

  5. Selinexor

    Karyopharm

    Myelofibrosis

    phase 3 small molecule active

    2 trials

  6. Selinexor

    Karyopharm

    Dedifferentiated Liposarcoma

    phase 3 small molecule completed

    1 trial

  7. Selinexor

    Karyopharm

    Endometrial Cancer

    phase 3 small molecule active

    2 trials

  8. Selinexor (combination therapy)

    Karyopharm

    Relapsed/Refractory Diffuse Large B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  9. A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

    Karyopharm

    Relapsed/Refractory DLBCL, Relapsed/Refractory DLBCL, Relapsed/Refractory DLBCL

    phase 2 other active

    1 trial

  10. Abemaciclib, dexamethasone, ixazomib, pomalidomide

    Karyopharm

    Relapsed Refractory Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  11. Cyclophosphamide

    Karyopharm

    Myeloma Multiple

    phase 2 small molecule terminated

    1 trial

  12. Decitabine

    Karyopharm

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  13. Docetaxel

    Karyopharm

    Recurrent Squamous Cell Lung Carcinoma

    phase 2 small molecule terminated

    1 trial

  14. Elotuzumab, Selinexor, and Dexamethasone (ESd)

    Karyopharm

    Relapsed Multiple Myeloma

    phase 2 small molecule terminated

    1 trial

  15. Ibrutinib

    Karyopharm

    Lymphoma

    phase 2 small molecule active

    1 trial

  16. KPT-8602

    Karyopharm

    Relapsed/Refractory Multiple Myeloma (RRMM)

    phase 2 small molecule completed

    1 trial

  17. Ondansetron Aurobindo 8 mg Filmtabletten, Dexamethasone 4 mg tablets, ZYPREXA 2.5 mg coated tablets, SELINEXOR, Bortezomib Accord 3.5 mg powder for solution for injection

    Karyopharm

    Penta-refractory multiple myeloma and triple-class refractory multiple myeloma

    phase 2 small molecule active

    1 trial

  18. Open Label Selinexor

    Karyopharm

    Thymoma

    phase 2 small molecule terminated

    1 trial

  19. PALONOSETRON, Jakavi 10 mg tablets, ONDANSETRON, NETUPITANT, APREPITANT, PACRITINIB, Jakavi 5 mg tablets, SELINEXOR

    Karyopharm

    moderate thrombocytopenia, JAK inhibitor-naïve myelofibrosis

    phase 2 small molecule active

    1 trial

  20. Pacritinib

    Karyopharm

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  21. Pembrolizumab

    Karyopharm

    Advanced Urothelial Carcinoma

    phase 2 mab terminated

    1 trial

  22. SELINEXOR

    Karyopharm

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  23. Selinexor

    Karyopharm

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  24. Selinexor

    Karyopharm

    Acute Myeloid Leukemia (Relapsed/Refractory)

    phase 2 small molecule completed

    1 trial

Drugs (1)

Search drugs →

  1. selinexor

    NEXPOVIO

    ORAL approved

    L01XX66

Patents (8)

Search patents →

  1. US 12371420

    Polymorphs of Selinexor

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12331040

    Substituted benzofuranyl and benzoxazolyl compounds and uses thereof

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12318386

    Combination of XPO1 inhibitors and second agents for the treatment of prostate cancer

    Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12291508

    Hydrazide containing nuclear transport modulators and uses thereof

    Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11945794

    Nuclear transport modulators and uses thereof

    Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11807629

    Polymorphs of Selinexor

    Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11787771

    Hydrazide containing nuclear transport modulators and uses thereof

    Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11753401

    Polymorphs of Selinexor

    Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Karyopharm?

Karyopharm (KPTI) is a pharma company. headquartered in NEWTON, MA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 8 patents to this profile..

What pipeline programs does Karyopharm sponsor?

We track 24 ClinicalTrials.gov-linked programs for Karyopharm, including ONDANSETRON ZYDUS 8 mg, comprimé orodispersible, Jakavi 5 mg tablets, EMEND 125 mg+80 mg hard capsules, Jakavi 15 mg tablets, Jakavi 20 mg tablets, PALONOSETRON, NETUPITANT, Akynzeo 300 mg/0.5 mg hard capsules, Selinexor placebo for 20 mg tablets formulated for oral administration., Jakavi 10 mg tablets, SELINEXOR, ONDANSETRON and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Karyopharm company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.